FACACLASSIC

Note: An Annual Comprehensive Review, as required by §7 of the Federal Advisory Committee Act, is conducted each year on committee data entered for the previous fiscal year (referred to as the reporting year). The data for the reporting year is not considered verified until this review is complete and the data is moved to history for an agency/department. See the Data From Previous Years section at the bottom of this page for the committee’s historical, verified data.

Details on agency responses to committee recommendations can be found under the Performance Measures section for each committee in the fields “Agency Feedback” and “Agency Feedback Comment.”

HHS - 73655 - Interagency Pain Research Coordinating Committee - Statutory (Congress Created)

GENERAL INFORMATION

Committee Name	Interagency Pain Research Coordinating Committee	Agency Name	Department of Health and Human Services
Fiscal Year	2025	Committee Number	73655
Original Establishment Date	7/8/2010	Committee Status	Chartered
Actual Termination Date		Committee URL	https://iprcc.nih.gov/
Actual Merged Date		Presidential Appointments*	No
New Committee This FY	No	Max Number of Members*	19
Terminated This FY	No	Designated Fed Officer Position Title*	Health Science Policy Advisor
Merged This FY		Designated Federal Officer Prefix
Current Charter Date	7/8/2024	Designated Federal Officer First Name*	Irene
Date Of Renewal Charter	7/8/2026	Designated Federal Officer Middle Name	Amy
Projected Termination Date		Designated Federal Officer Last Name*	Adams
Exempt From Renewal*	No	Designated Federal Officer Suffix	PhD
Specific Termination Authority		Designated Federal Officer Phone*	301-435-0110
Establishment Authority*	Statutory (Congress Created)	Designated Federal Officer Fax*	301-402-2060
Specific Establishment Authority*	42 USC 284	Designated Federal Officer Email*	amy.adams2@ninds.nih.gov
Effective Date Of Authority*	1/1/2010
Exempt From EO 13875 Discretionary Cmte	Not Applicable
Committee Type*	Continuing
Presidential*	No
Committee Function*	Scientific Technical Program Advisory Board

RECOMMENDATION/JUSTIFICATIONS

Agency Recommendation*	Continue
Legislation to Terminate Required	Not Applicable
Legislation Status	Not Applicable
How does cmte accomplish its purpose?*	The Interagency Pain Research Coordinating Committee accomplishes its purpose by meeting regularly to coordinate all pain research efforts within HHS and across other relevant Federal Agencies. These meetings have resulted in recommendations to ensure no unnecessary duplication of effort, to identify critical gaps in knowledge, to disseminate information, and develop strategies for pain prevention, treatment, management, education, and research. The Committee also establishes expert work groups to address IPRCC goals and objectives.
How is membership balanced?*	The Committee is composed of not more than 7 voting Federal representatives from agencies that conduct pain care research and treatment and 12 non-Federal voting members. The 12 non-Federal members include (a) 6 non-Federal members from among scientists, physicians, and other health professionals and (b) 6 non-Federal members from members of the general public who are representatives of leading research, advocacy, and service organizations for individuals with pain-related conditions.
How frequent & relevant are cmte mtgs?*	The committee met once in this reporting period.
Why advice can't be obtained elsewhere?*	The composition of the committee provides a unique balance of expertise and opinions that cannot be obtained totally from federal staff across multiple agencies or on an ad hoc basis because of the diversity in scientific and non-scientific viewpoints needed, the importance of non-federal perspectives, and the need for continuity as the Committee considers issues over time.
Why close or partially close meetings?	N/A
Recommendation Remarks	Based on the assignment of duties, the Designated Federal Officer and the committee decision maker positions are both held by Dr. Irene Amy Adams Reports: The committee did not produce any public reports. The following members were on administrative extensions during the reporting period: Paul Arnstein, Tamara Baker, Scott Fishman, Elisabeth Kato, Helene Langevin, Renee Manworren, and Kate Nicholson. The Committee Charter authorizes up to 19 voting members, including Special Government Employees (SGEs) and Regular Government Employees (RGEs). The Charter also permits the inclusion of non-voting members, as determined appropriate by the Secretary, who are not counted toward the total number of authorized members. There are currently two Ex-Officio members: Shannon Zenk and Nora Volkow.

PERFORMANCE MEASURES

Outcome Improvement To Health Or Safety*	Yes	Action Reorganize Priorities*	No
Outcome Trust In Government	No	Action Reallocate Resources	No
Outcome Major Policy Changes	No	Action Issued New Regulations	No
Outcome Advance In Scientific Research	Yes	Action Proposed Legislation	No
Outcome Effective Grant Making	No	Action Approved Grants Or Other Payments	No
Outcome Improved Service Delivery	No	Action Other	Yes
Outcome Increased Customer Satisfaction	No	Action Comment	NIH is leading an effort to evaluate responsiveness of federally funded pain research to the priorities identified in the FPRS. The IPRCC is also leading workgroups in areas of high importance for pain research: "Workforce and Provider Training in Pain Research", "Implemental Science in Pain Management" and "Resilience and Prevention in Chronic Pain" to facilitate activities in these areas.
Outcome Implement Laws/Reg Requirements	No	Grants Review*	No
Outcome Other	No	Number Of Grants Reviewed	0
Outcome Comment	NA	Number Of Grants Recommended	0
Cost Savings*	Unable to Determine	Dollar Value Of Grants Recommended	$0.00
Cost Savings Comment	The committee's mission includes making recommendations to ensure that the activities of the National Institutes of Health and other Federal agencies are free of unnecessary duplication of effort and making recommendations on how to expand partnerships between public entities and private entitites to expand collaborative, cross-cutting research.	Grants Review Comment	NA
Number Of Recommendations*	10	Access Contact Designated Fed. Officer*	Yes
Number Of Recommendations Comment	The committee did not make any new recommendations this year.	Access Agency Website	Yes
% of Recs Fully Implemented*	75.00%	Access Committee Website	Yes
% of Recs Fully Implemented Comment	N/A	Access GSA FACA Website	Yes
% of Recs Partially Implemented*	25.00%	Access Publications	No
% of Recs Partially Implemented Comment	Science advances are reported annually. The National Pain Strategy implementation is expected to take five years. The Federal Pain Research Strategy priority research areas benchmark currently are being reviewed. Updates on priority research areas identified by the Federal Pain Research Strategy are provided regularly to the IPRCC and NIH. Many priority research areas were funded by the NIH HEAL initiative.	Access Other	No
Agency Feedback*	Yes	Access Comment	Information on the IPRCC may be obtained from Carolyn Conlin at carolyn.conlin@nih.gov or from the website: https://iprcc.nih.gov/
Agency Feedback Comment*	The committee receives feedback through minutes and reports presented at meetings. The IPRCC Designated Federal Officer has provided updates on IPRCC activities related to relevant legislation (e.g. SUPPORT ACT) to federal agencies and congressional staff as appropriate. The IPRCC also receives feedback from federal agencies on relevant activities as mandated in the ACA and SUPPORT ACT through their regularly held meetings. Information is provided to the public at each meeting. The public can view information related to the Committee through the committee’s official website.	Narrative Description*	As specified in Public Law 111-148 (“Patient Protection and Affordable Care Act”) and amended in H.R. 6, (“Support for Patients and Communities Act”) the Committee will: (A) develop a summary of advances in pain care research supported or conducted by the Federal agencies relevant to the diagnosis, prevention, treatment, and management of pain and diseases and disorders associated with pain, including information on best practices for the utilization of non-pharmacologic treatments, non-addictive medical products, and other drugs or devices approved or cleared by the Food and Drug Administration; (B) identify critical gaps in basic and clinical research on the symptoms and causes of pain, including the identification of relevant biomarkers and screening models and the epidemiology of acute and chronic pain; the diagnosis, prevention, treatment, and management of acute and chronic pain, including with respect to non-pharmacologic treatments, non-addictive medical products, and other drugs or devices approved or cleared by the Food and Drug Administration; and risk factors for, and early warning signs of, substance use disorders in populations with acute and chronic pain; (C) make recommendations to the Director of NIH to ensure that the activities of the National Institutes of Health and other Federal agencies are free of unnecessary duplication of effort; on how best to disseminate information on pain care and epidemiological data related to acute and chronic pain; and on how to expand partnerships between public entities and private entities to expand collaborative, cross-cutting research.

COSTS

1. Payments to Non-Federal Members*	$2,000.00	1. Est Paymnts to Non-Fed Membrs Nxt FY*	$4,800.00
2. Payments to Federal Members*	$2,207.00	2. Est. Payments to Fed Members Next FY*	$10,298.00
3. Payments to Federal Staff*	$217,776.00	3. Estimated Payments to Federal Staff*	$252,739.00
4. Payments to Consultants*		4. Est. Payments to Consultants Next FY*
5. Travel Reimb. For Non-Federal Membrs*		5. Est Travel Reimb Non-Fed Membr nxtFY*	$9,168.00
6. Travel Reimb. For Federal Members*		6. Est Travel Reimb For Fed Members*
7. Travel Reimb. For Federal Staff*		7. Est. Travel Reimb to Fed Staf Nxt FY*
8. Travel Reimb. For Consultants*		8. Est Travel Reimb to Consltnts Nxt FY*
10. Other Costs	$11,912.00	10. Est. Other Costs Next FY*	$20,379.00
11. Total Costs	$233,895.00	11. Est. Total Next FY*	$297,384.00
Date Cost Last Modified	9/25/2025 12:46 PM	Est. Fed Staff Support Next FY*	0.50
Federal Staff Support (FTE)*	0.50	Est Cost Remarks
Cost Remarks	Costs were lower in FY25, as the IPRCC met one time. The Committee hopes to resume a regular schedule for FY26.

Interest Areas

Category Area Health Health Care Public Health Treatment

Custom Links

Committee Level Reports